Evolution of high-titer virus-like vesicles for vaccine applications
US10435712B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 11, 2015 |
| Grant date | Oct 8, 2019 |
| Priority date | — |
| Expiry date | May 11, 2035 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the discovery of a high titer hybrid-virus vector that gives rise to high titer virus like vesicles (VLVs) that can be used as a vaccine. The invention includes compositions and methods of generating an evolved hybrid-virus vector vaccine and selecting high titer VLVs, methods of treating and/or preventing or immunizing against, a specific disease or disorder, and methods of inducing a memory T cell and B cell immune response in a subject administered the VLV composition produced thereby. Furthermore, the invention encompasses a pharmaceutical composition for vaccinating a subject as well as a high titer protein expression system.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.